Cover Kidney News
Volume/Issue:
Volume 15: Issue 9
Page:
22
Publication Date:
01 Sep 2023
Online Publication Date:
01 Sep 2023
  • Figure 1
    View in gallery
    Figure 1

    GLP1ra orforglipron and injectable triple agonist retatrutide

Figure 1

GLP1ra orforglipron and injectable triple agonist retatrutide
  • 1.

    Wharton S, et al.; GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med (published online ahead of print June 23, 2023). doi: 10.1056/NEJMoa2302392; https://www.nejm.org/doi/10.1056/NEJMoa2302392

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Jastreboff AM, et al.; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med 2023; 389: 514–526. doi: 10.1056/NEJMoa2301972

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Knop FK, et al.; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (published online ahead of print June 23, 2023). doi: 10.1016/S0140-6736(23)01185-6; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Perkovic V, et al. FC 123: Baseline characteristics of the Flow trial population: Kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant 2022; 37 (Suppl 3). https://academic.oup.com/ndt/article/37/Supplement_3/gfac126.002/6578114?login=true

    • PubMed
    • Search Google Scholar
    • Export Citation

High Tides: Innovations in Obesity Treatment Bring Change to the Future of Nephrology

Evan M. Zeitler Evan M. Zeitler, MD, and Koyal Jain, MD, are with the Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina Kidney Center, University of North Carolina at Chapel Hill.

Search for other papers by Evan M. Zeitler in
Current site
Google Scholar
PubMed Close
and
Koyal Jain Evan M. Zeitler, MD, and Koyal Jain, MD, are with the Division of Nephrology and Hypertension, Department of Medicine, University of North Carolina Kidney Center, University of North Carolina at Chapel Hill.

Search for other papers by Koyal Jain in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 15: Issue 9
Publication Date:
01 Sep 2023
Page:
22
Restricted access
Save